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Lysosomal Membrane Permeabilization is an Early
Event in Sigma-2 Receptor Ligand Mediated Cell
Death in Pancreatic Cancer
John R Hornick1, Suwanna Vangveravong3, Dirk Spitzer1, Carmen Abate4, Francesco Berardi4,
Peter Goedegebuure1,2, Robert H Mach3 and William G Hawkins1,2*
Abstract
Background: Sigma-2 receptor ligands have been studied for treatment of pancreatic cancer because they are
preferentially internalized by proliferating cells and induce apoptosis. This mechanism of apoptosis is poorly
understood, with varying reports of caspase-3 dependence. We evaluated multiple sigma-2 receptor ligands in this
study, each shown to decrease tumor burden in preclinical models of human pancreatic cancer.
Results: Fluorescently labeled sigma-2 receptor ligands of two classes (derivatives of SW43 and PB282) localize to
cell membrane components in Bxpc3 and Aspc1 pancreatic cancer cells and accumulate in lysosomes. We found
that interactions in the lysosome are critical for cell death following sigma-2 ligand treatment because selective
inhibition of a protective lysosomal membrane glycoprotein, LAMP1, with shRNA greatly reduced the viability of
cells following treatment. Sigma-2 ligands induced lysosomal membrane permeabilization (LMP) and protease
translocation triggering downstream effectors of apoptosis. Subsequently, cellular oxidative stress was greatly
increased following treatment with SW43, and the hydrophilic antioxidant N-acetylcysteine (NAC) gave greater
protection against this than a lipophilic antioxidant, α-tocopherol (α-toco). Conversely, PB282-mediated cytotoxicity
relied less on cellular oxidation, even though α-toco did provide protection from this ligand. In addition, we found
that caspase-3 induction was not as significantly inhibited by cathepsin inhibitors as by antioxidants. Both NAC and
α-toco protected against caspase-3 induction following PB282 treatment, while only NAC offered protection
following SW43 treatment. The caspase-3 inhibitor DEVD-FMK offered significant protection from PB282, but not
SW43.
Conclusions: Sigma-2 ligand SW43 commits pancreatic cancer cells to death by a caspase-independent process
involving LMP and oxidative stress which is protected from by NAC. PB282 however undergoes a caspase-
dependent death following LMP protected by DEVD-FMK and α-toco, which is also known to stabilize the
mitochondrial membrane during apoptotic stimuli. These differences in mechanism are likely dependent on the
structural class of the compounds versus the inherent sigma-2 binding affinity. As resistance of pancreatic cancers
to specific apoptotic stimuli from chemotherapy is better appreciated, and patient-tailored treatments become
more available, ligands with high sigma-2 receptor affinity should be chosen based on sensitivities to apoptotic
pathways.
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Introduction
Sigma receptors have been intensely studied for their
applications in both neuropharmacology and oncology.
Two subtypes of sigma receptors are known, sigma-1 and
−2, which were classically characterized by differences in
their relative binding affinity of [3H]-(+)-pentazocine
(sigma-1> sigma-2) [1] and [3H]-1,3 di-ortho-tolylguani-
dine ([3H]-DTG) (sigma-1 = sigma-2) [2] because of lack
of genetic identification of the sigma-2 receptorfor
many years. However, we have recently identified pro-
gesterone receptor membrane component 1 (PGRMC1)
protein complex as containing the sigma-2 receptor
binding site [3]and others recently found PGRMC1/
sigma-2 to be elevated in tumors and serum of lung can-
cer patients [4].
Sigma-2 receptors are overexpressed in multiple tumor
types including breast, pancreas, neuroblastoma, bladder,
and lung as reviewed [5], which has allowed further de-
velopment of these ligands as radiotracers for the im-
aging of cancer [6]. In addition, various sigma-2 receptor
ligands have been extensively studied for their effective-
ness in the treatment of solid tumors due to their prefer-
ential uptake in proliferating cells [7]. We have
previously shown that sigma-2 receptors are upregulated
in pancreatic cancer, that sigma-2 ligands can induce
caspase-3-mediated apoptisis, and are effective in pre-
clinical models of pancreatic cancer [8–10].
Sigma-2 receptor ligands that have been investigated
for efficacy in the treatment of cancer induce apoptosis
in caspase-3 dependent and independent manners, but
the exact mechanism of cell death is still not well char-
acterized. For example, in SK-N-SH neuroblastoma
cells caspase-3 was not activated by CB-64D [11], nor
did caspase inhibitors afford protection against cell
death in MCF-7 breast cancer cells [12]. Caspase-3 is
however activated in MCF-7 [13] and in murine pan-
creatic adenocarcinoma Panc02cells [10] bysiramesine,
though caspase-3 inhibitor did not rescue viability in
either case. With another compound, PB28, no cas-
pase-3 activity was observed in MCF-7 [14] or SK-N-
SH cells [15].
Thus, while various sigma-2 receptor ligands are cap-
able of inducing apoptosis in tumor cells, the activation
of caspase-3 and upstream signaling events leading to
this appear to be specific to particular ligand and cell
type. In this study, we sought to more closely study the
apoptotic pathway induced by a number of structurally
distinct sigma-2 receptor ligands in pancreatic cancer,
which have proven efficacious in preclincal models. With
knowledge of chemotherapy resistance to apoptotic
stimuli depending on different mechanisms, we may
more appopriately choose effective therapies.
Results
Structurally distinct sigma-2 receptor ligands inhibit
growth of pancreatic cancer
Multiple structurally distinct compounds (Figure 1) with
high affinity for sigma-2 receptors were tested for cyto-
toxicity against multiple pancreatic cancer cell lines
in vitro (Table1) and screened for efficacy in a mouse
model of pancreatic cancer with Panc02 cells (Additional
file 1: figure S1). Compounds were further tested in
athymic nude mice bearing human Bxpc3 subcutaneous
tumorsand treated daily with equimolar doses of these
sigma-2 receptor ligands. These mice with established
tumors were treated for eleven days and compared to
vehicle, SV119, SW43, PB28, and PB282 each signifi-
cantly decreased tumor volume (Figure 2).
Distinct sigma-2 receptor ligands induce lysosomal
membrane permeabilization (LMP)
Recently characterized fluorescent sigma-2 receptor
ligands SW120 (derivative of SW43) [16] and PB385 (de-
rivative of PB282) [17], colocalize with LysoTracker Red
in Bxpc3 pancreatic cancer cells by confocal microscopy
(Figure 3), and also appreciated by fluorescent
Figure 1 Structures. Sigma-2 receptor ligands SW43 and SW120,
derivatives of N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N-
(2-methoxy-5-methylphenyl) carbamate hydrochloride (SV119), and
PB282 and PB385, derivatives of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-
tetrahydro-naphthalen-1-yl)propyl]-piperazine dihydrochloride (PB28).
Affinity to sigma-1/2 (σ2) receptor given by Ki (nM).
Table 1 Pancreatic cancer cell line viability, IC50 (μM),
following sigma-2 receptor ligand treatment (24 hr)
Panc02 Bxpc3 Aspc1
Mean SEM n Mean SEM n Mean SEM n
SV119 92 10 4 97 16 3 192 41 4
SW43 26 5 4 56 14 3 65 12 4
PB28 73 10 4 96 16 3 244 48 4
PB282 79 16 4 82 20 3 135 10 4
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microscopy in Bxpc3 and Aspc1 (Additional file 2 figure
S2A). Bxpc3 cells preloaded with acridine orange (AO,
2 μg/mL), had decreased retention of orange dye in the
lysosome (Figure 3, bottom panel) following treatment
with SW43 and PB282, and displayed increased green
fluorescence as dye escaped and bound with nucleic
acids. Similar results were observed in Aspc1 cells (Add-
itional file 2 figure S2A). The pH gradient of the lyso-
some is actively driven by a V-Type ATPase H+ pump
[18], and its inhibition with concanamycin A (CMA)
prevented dye retention in the lysosome. As well, hydro-
xychloroquine (HCQ), originally used for treatment of
malaria [19] and extensively studied as a lysosomotropic
detergent [20] showed decreased dye retention (positive
control) (Additional file 3 figure S3A). SV119 and PB28,
with high affinity to sigma-2 receptors, displayed leake-
age of lysosomal dyes by acridine orange,and leakage by
all compounds was confirmed with LysoTracker Green
(Additional file 3 figure S3B).
Compromising lysosomal membrane integrity sensitizes
pancreatic cancer cells to sigma-2 receptor ligand
mediated LMP and cell death
LAMP1 and LAMP2 are large, closely homologous,
glycoprotein constituents of the lysosomal membrane
that contribute to protection of the membrane against
Figure 2 In vivo efficacy of sigma-2 receptor ligands. Athymic
nude mice inoculated subcutaneously with 1x106 Bxpc3 cells were
treated daily with sigma-2 receptor ligands SV119, SW43, PB28, or
PB282 when tumors reached an average of 5 mm in diameter. Data
represents mean± SEM, n = 7–10 per group, * p< 0.05.
Figure 3 Sigma-2 receptor ligands localize to lysosomes and induce lysosomal membrane permeabilization. Upper two rows, confocal
images of SW120 and PB385 (100 nM) in Bxpc3 cells, left (green), LysoTracker Red (25 nM), middle (red), and overlay right. Bottom row, acridine
orange (2 μg/mL) staining for lysosomal integrity in Bxpc3 cells treated with vehicle, left, PB282 (30 μM) middle, or SW43 (30 μM) right for one
hour. Scale bar = 20 μm.
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the acidic enviroment within this organelle [21]. We
hypothesized that decreasing the content of LAMP1 in
the lysosome would subject the membrane to increased
stress and susceptibility to permeabilization. pLKO.1-
LAMP1 and pLKO.1-Neg shRNA lentiviral constructs
were used to transform and select Bxpc3 (Figure 4A)
cells with decreased expression of LAMP1 and LAMP2
(Figure 4A). LAMP1 shRNA-expressing cells signifi-
cantly retained less fluorescence of LysoTracker Green
(Figure 4B), mean fluorescence 61.6 ± 0.1 percent of ve-
hicle, with moderate decreases following treatment with
SW43 or PB282. LAMP1 knockdown significantly
increased susceptibility of Bxpc3 cells to cell death fol-
lowing treatment with SW43 and PB28, with less protec-
tion observed in the lower range of toxicity with HCQ
(Figure 4C).
Lysosomal accumulation of sigma-2 receptor ligands is
required for LMP and cell death
Bxpc3 cells were treated with CMA (10 nM) for 60 min-
utes in order to effectively inhibit the pH gradient
across the lysosomal membrane. Subsequent accumula-
tion of the fluorescently labeled sigma-2 receptor
ligands SW120 and PB385 showed marked decrease of
fluorescence intensity by flow cytometry (Figure 5A).
Bxpc3 cells pretreated with CMA were more viable fol-
lowing treatment with sigma-2 ligands, but the response
was greater for SW43 and HCQ compared to PB282
(Figure 5B). To determine whether LMP lead to re-
lease of proteases into the cytoplasm, the cytosolic
fraction was isolated from the lysosomal fraction by
selective permeabilization of the plasma membrane
with digitonin, and cleavage ofcathepsin B substrate Z-
RR-AMC was assessed. All compounds increased Z-
RR-AMC cleavage within one hour of treatment, and
CMA decreased this Z-RR-AMC cleavage to baseline
(Figure 5C). CA-074-Me and pepstatin A decreased
cleavage for all compounds as well, with the exception
that pepstatin A was not observed to inhibit cleavage
following SW43 treatment. Functional rescue of viabil-
ity in the presence of CA-074-Me and pepstatin A was
assessed at 24 hours following treament, and pepstatin
A was observed to rescue viability across a titrated
dose range for all compounds, while CA-074-Me had a
lesser effect, though the observed differences did not
reach statistical significance (Figure 5D).
Figure 4 Sensitization to lysosomal membrane permeabilization and cell deathby LAMP1 shRNA. (A) Bxpc3 cells transformed with
pLKO.1-LAMP1 or pLKO.1-Neg Ctl confirmed for knockdown of LAMP1/2 by flow cytometry. (B) Lysosomal retention of LysoTracker Green by flow
cytometry of transformed cells treated with DMSO vehicle, SW43, or PB282 for one hour. Data represents mean fluorescence normalized to DMSO
treated pLKO.1-Neg cells, n = 3. (C) Viability of transformed cells following 24 hour treatment with SW43, PB282, HCQ. Data represents percent
viability compared to DMSO treated cells, n = 3, * p< 0.05.
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Antioxidants are protective of cellular toxicity
Sufficient LMP leads to apoptosis through release of spe-
cific mediators of crosstalk with the mitochondria such
as cathepsins, and release or stimulation of reactive oxy-
gen species (ROS) [22]. Though cancer cells typically
have a higher than normal content of ROS due to rela-
tive anoxia, additional oxidative stress is lethal due to
oxidation and disruption of membrane lipids, proteins,
and DNA [23]. To assess the involvement of ROS in
apoptosis following sigma-2 receptor ligand treatement,
we examined the influence of antioxidants on cell death.
ROS production in Bxpc3 cells following 24 hour treat-
ment with SW43 (60 μM), PB282 (90 μM), and H2O2
(100 μM) was detected with 5-(and-6)-chloromethyl-
2',7'-dichlorodihydrofluorescein diacetate acetyl ester
(CM-H2DCFDA) as described in the Materials and
Methods. Substantial amounts of ROS were detected
with SW43 and H2O2, but no ROS was detectable after
treatment with PB282. ROS was decreased following
SW43 treatment in the presence of antioxidants α-toc-
opherol (α-toco) and n-acetylcysteine (NAC), while ROS
from H2O2 was only decreased by NAC (Figure 6A).
The impact of antioxidants on cell viability was assessed
following 24 hour treatment with SW43 and PB282.
Antioxidants protected against sigma-2 receptor ligand
induced cell death, with NAC protecting against SW43
to a greater extent than α-toco. Interestingly, while
PB282 treatment did not result in detectable ROS re-
lease, both antioxidants increased tumor cell viability
after PB282 exposure (Figure 6B).
Figure 5 Sigma-2 receptor ligand-mediated cell death is dependent on lysosomal accumulation and membrane permeabilization. (A)
Accumulation of sigma-2 receptor ligands SW120 and PB385 in Bxpc3 cells following inhibition of lysosomal pH gradient with the V-ATPase
inhibitor concanamycin A (CMA) (10 nM) detected by flow cytometry. (B) Cell viability following 24 treatment with sigma-2 receptor ligands
SW43 and PB282 or lysosomal detergent hydroxychlorquine (HCQ) in the presence of CMA (10 nM). Data represents percent viability compared
to DMSO treated cells, n = 3, p< 0.05 (C) Cleavage of fluorescent peptidase substrate Z-RR-AMC following one hour treatment with SW43
(30 μM), PB282 (30 μM), or HCQ (60 μM), in the presence of CMA (10 nM) or peptidase inhibitors CA-074-Me (10 μM) and pepstatin A (100 μM).
Data is relative to DMSO treated cells and is representative of experiments performed in triplicate. (D) Cell viability following 24 hour treatment
with SW43, PB282, or HCQ in the presence of CA-074-Me or pepstatin A. Data represents percent viability compared to DMSO treated cells, n = 3.
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Caspase-3 inhibition by lipophilic antioxidant correlates
with caspase dependence
Caspase-3 has been extensively studied as a mechanism
of sigma-2 receptor ligand mediated apoptosis, and we
wished to examine the impact of ROS stimulation by
structurally different ligands. Basal caspase-3 activity by
SW43, PB282, and HCQ treatment following 24 hours
was detected by cleavage of Z-DEVD-AMC as previously
described [10] (Figure 7A). This activation was inhibited
by α-toco following PB282 treatment, but not following
SW43 or HCQ treatment. NAC, however, decreased cas-
pase-3 activation by all compounds. DEVD-FMK cas-
pase-3 inhibitor was used as a positive control for
inhibition in all experiments. One hour pretreatment
with DEVD-FMK, followed by 24 hour treatment with
SW43, PB282, or HCQ showed little protection for
SW43 and HCQ, while PB282 mediated cytotoxicity was
protected to a much greater extent following caspase-3
inhibition (Figure 7B). Interestingly, caspase-3 activity
was not observed in Aspc1 cells (Additional file 3 figure
S3C), a cell line with less sensitivity to PB282 (Additional
file 3 figure S3D).
Discussion
Recent synthesis of fluorescently labeled analogs of
SV119 (SW120) and PB28 (PB385), allowing live cell im-
aging, has shown sigma-2 receptor ligand subcellular
localization to the membrane components of the cell
ultrastructure [16,17]. In various pancreatic cancer cell
lines we have observed similar results, and hypothesized
that strong uptake into the endo-lysosomal compart-
ment induces lysosomal membrane permeabilization
(LMP). In addition, weakly basic amines as a class of
drugs have been shown to induce LMP [24] and cell
death [25], and the amine groups present on sigma-2 re-
ceptor ligands suggest they can induce LMP. We exam-
ined here whether this could influence the caspase-3
activation in pancreatic cancer we observed earlier [8-
10] and found that LMP occurs shortly following treat-
ment with a variety of structurally diverse sigma-2 re-
ceptor ligands, verified by both AO and LysoTracker
release from the lysosome.
Uptake of fluorescently labeled compounds was
inhibited by blocking the lysosomal pH gradient with
concanamycin A (CMA), a specific inhibitor of the V-
Type ATPase [26,27], and translated into significant
viability protection following treatment. SW43 was a
stronger inducer of LMP, with greater protection from
CMA pretreatment than for PB282. This that some
sigma-2 receptor ligands have a greater propensity to
influence the lysosomal death pathway Chemical struc-
ture differences may be responsible for this difference.
For instance, the structure of the N-(9-(6-Amino-
hexyl)-9-azabicyclo[3.3.1]-nonan-3α-yl)-N-(2-methoxy-
5-methylphenyl) carbamate hydrochloride (SV119)
derivatives contain an alkyl extension with terminal
amine group that is not present in the 1-cyclohexyl-4-
[3-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-
Figure 6 Antioxidants are protective of cellular toxicity. (A) ROS detection by flow cytometry in Bxpc3 cells with 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) following 24 hour treatment with SW43 (60 μM), PB282 (90 μM), or hydrogen
peroxide (H2O2, 100 μM) in the presence of lipophilic antioxidant α-tocopherol (α-toco) or hydrophilic antioxidant N-acetylcyteine (NAC). (B) Cell
viability following 24 hour treatment with SW43 or PB282 in the presence of α-toco or NAC. Data represents percent viability compared to DMSO
treated cells, n = 3, * p< 0.05.
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piperazine dihydrochloride (PB28) derivatives, a moiety
that increases lysosomal membrane insertion and
permeabilization [28].
The lysosomal associated membrane proteins 1 and 2
(LAMP1/2) are homologous proteins of the lysosomal
membrane [21,29,30], where they are highly glycosylated
and to contribute to protection of the lysosomal mem-
brane and its proteins from the hostile constituents such
as hydrogen ion and proteases [31]. In addition, down-
regulation of LAMP1/2 have been previously shown to
sensitize cells to lysosomal mediated death pathways
[32], and we wished to confirm that sigma-2 receptor
ligands act through a component of this pathway by de-
creasing LAMP1 expression with a lentivirus driven
shRNA in Bxpc3 cells. Transformed cells had weaker
lysosomes that retained less LysoTracker and the effect
was additive with sigma-2 receptor ligand. Overall
LysoTracker Green uptake was decreased as assessed by
flow cytometry, which could have occurred by either a
decreased number of lysosomes, or increased leakage
across the membrane. We believe that the enhanced kill-
ing of transformed cells was due to compromise of the
membrane integrity rather than decreased number of
lysosomes based on the above finding that sigma-2 lig-
and accumulation in lysosomes is a necessary compo-
nent of cell death.
LMP mediated cell death has been extensively studied
recently in the context of apoptosis induction in cancer
cells [22,33,34]. The exact mechanism of LMP is still un-
determined, and whether it involves pore formation or
selective movement of contents, dyes of increasing mo-
lecular weight and size can be differentially released in-
dicating some selectivity to LMP. A large number of
known inducers of LMP exist, reviewed in [22], and cul-
minate in the release of proteases such as cathepsin B,
D, and L, amonst others. Following treatment with
sigma-2 receptor ligands, or hydroxychloroquine, we
observed a near doubling of Z-RR-AMC cleavage within
one hour, which was inhibited completely by CMA and
CA-074-Me, supporting the above finding that uptake of
the compound into the lysosome is a critical step in
LMP mediated cell death.
Cancer cells can undergo both caspase-dependent and
independent pathways of cell death following LMP, de-
pending on the degree of insult [22]. Cathepsins mediate
crosstalk between the lysosome to the mitochondria [35],
where a caspase-dependent pathway is stimulated with
cytochrome c release and superoxide production [36].
With larger insults, a caspase-independent death path-
way may be followed with release of cathepsins, cytosolic
acidification, and caspase-2 activation [22]. ROS produc-
tion due to either pathway can act as both an effector
and initiator of cell death. Amongst known inducers of
LMP, oxidative stress itself ultimately leads to lipid per-
oxidation of the membrane with permeabilization [37].
Thus, production of ROS following treatment can amp-
lify LMP.
Protection against ROS can be by antioxidants or
intracellular enzymes such as superoxide dimutase, cata-
lase, and glutathione peroxidase. NAC is an small diffus-
ible, hydrophobic antioxidant that is a precursor to
glutathione, a cellular thiol-reducing agent oxidized by
glutathione peroxidase in the reduction of hydrogen per-
oxide to water. In this study, NAC protected against cell
death by SW43 to a greater extent than α-toco, while α-
toco protected against PB282 more than NAC. While
the mechanism of α-toco protection against oxidative
stress is thought to be by prevention of membrane lipid
peroxidation, and NAC as a general reducing agent, we
believe this indicates key differences in the intracellular
sites exposed to oxidative stress by sigma-2 receptor
Figure 7 Caspase-3 inhibition by lipophilic antioxidant
correlates with caspase dependence. (A) Caspase-3 inhibition by
the hydrophobic antioxidant α-tocopherol (α-toco), hydrophilic
antioxidant N-acetylcyteine (NAC), or caspase-3 inhibitor DEVD-FMK
(1 μM) in Bxpc3 cells following 24 hour treatment with SW43
(30 μM), PB282 (90 μM), or HCQ (90 μM). Data represents normalized
inhibition compared to caspase-3 inducing treatment, n = 3,
p< 0.05. (B) Cell viability following 24 hour treatment with SW43 or
PB282 in the presence of α-toco or NAC. Data represents percent
viability compared to DMSO treated cells, n = 3, * p< 0.05.
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ligands. Intracellular ROS was detected with CM-
H2DCFDA following SW43, but not PB282. This was
decreased by both α-toco and NAC following SW43
treatment, but only with NAC following H2O2, suggest-
ing that H2O2treatment did not induce oxidative stress
in the membranes where the α-toco is present, while
SW43 may have. PB282 viability protection by antioxi-
dants is through a mechanism other than inhibiting oxi-
dative stress.
Alpha-tocopherol has been previously established to
protect cells from sigma-2 mediated mitochondrial ROS
production and caspase-3 release [10,38,39], and in this
study we observed that caspase-3 stimulated by PB282
was inhibited in the presence of this antioxidant, while it
did not protect that from SW43 or HCQ. In addition,
caspase-3 inhibitor DEVD-FMK provided ample protec-
tion against cell death following PB282 treatment, but
little following SW43 or HCQ despite detectable cas-
pase-3 activity. The observation that the Aspc1 cell line
did not induce caspase-3 activity following sigma-2 re-
ceptor ligand treatement, but retained cytotoxicity fol-
lowing lysosomal membrane permeabilization following
SW43 treatment, further suggests the susceptibility dif-
ferences are through slighty convergent pathways. Thus,
it is most likely that PB282 undergoes caspase-
dependent cell death following LMP that is mediated
through a mitochondrial pathway, protected by α-toco.
Conversely, SW43 undergoes caspase-independent cell
death following LMP, with oxidative stress playing a
stronger role in cell death.
Conclusions
Structurally diverse compounds with high affinity to
sigma-2 receptors are effective in decreasing tumor bur-
den in preclincial models of human pancreatic cancer.
While caspase-3 has been shown to be activated follow-
ing treatment with this class of compounds, conflicting
reports exist on caspase-3 dependence or independence
for cytotoxicity. We suggest that caspase-3 dependence
may be influenced by lysosomal mediated oxidative stress
in a compound specific manner amongst sigma-2 recep-
tor ligands. Better understanding of the susceptibility of
cancers to certain death pathways will ultimately allow
tailoring of sigma-2 receptor ligand treatment choice.
Materials and Methods
Cell Culture
Cell lines were maintained in RPMI media (GIBCO) sup-
plemented with L-glutamine (2 mM), (HEPES) (1 mM),
pyruvate (1 mM), sodium bicarbonate (0.075 %w/v),
penicillin and streptomycin (100 IU/mL), amphotericin
(0.25 μg/mL), and 10 % fetal bovine serum (Atlanta Bio-
logicals, Lawrenceville, GA). Cells were seeded at a
density of 2 x 105/mL unless otherwise stated and main-
tained in a humidified atmosphere of 5 % CO2 at 37°C.
Compounds
Sigma-2 receptor ligands were synthesized as previously
described [10,16,17,40-42]. The imaging dyes acridine or-
ange and LysoTracker Red were obtained from Invitro-
gen (Carlsbad, CA), FITC mouse anti-human CD107a
(LAMP1) and CD107b (LAMP2) antibodies from BD
Biosciences (Franklin Lakes, NJ), peptidase inhibitors
CA-074-Me and pepstatin A, and fluorogenic peptidase
substrate Z-RR-AMC from Enzo Life Sciences (Plymouth
Meeting, PA), caspase-3 inhibitor Z-DEVD-FMK from
R&D Systems (Minneapolis, MN); caspase-3 substrate
Ac-DEVD-AMC from Bachem Biosciences, Inc (King of
Prussia, PA); All other reagents were obtained from
Sigma-Alrich (St. Louis, MO) unless otherwise stated.
Compounds were dissolved in DMSO with final concen-
trations less than 0.3 %.
In vivo tumor treatment
Athymic nude mice from Harlan Bioproducts, Inc. were
inoculated subcutaneously with 1x106 Bxpc3 cells in the
right flank. Tumor sizes were monitored with calipers
and when tumors reached an average of 5 mm in diam-
eter, mice were randomized and treated daily with equi-
molar doses of sigma-2 receptor ligands SV119 (1.0 mg),
SW43 (1.1 mg), PB28 (0.9 mg), or PB282 (0.9 mg) resus-
pended in vehicle consisting of 5 % DMSO, 5 % EtOH,
and 10 % Cremophor in 1X PBS and injected intraperito-
neally. Data represents mean ± SEM, n = 7–10 per group.
Confocal microscopy
Cells grown on glass cover slips were incubated with
SW120 or PB385 (100 nM) in the presence of Lyso-
Tracker Red (25 nM) for 30 minutes at 37°C. Cells were
washed with PBS and fixed in 2 % paraformaldehyde for
30 minutes at 37°C prior to additional washing and
mounting with ProLong Gold antifade reagent. Confocal
imaging was performed on a Carl Zeiss Axiovert 100
inverted microscope, fitted with LSM 510 laser scanning
microscope camera and software. Images were collected
with filter bandwidths corresponding to 505–530 nm for
green, 560–615 nm for red, and> 650 nm for far red,
with 4 scans over 11.8 seconds.
Fluorescence microscopy
Cells grown on glass cover slips were loaded with acrid-
ine orange (2 μg/mL) for 15 minutes at 37°C prior to
treatment for one hour with compounds. Cover slips
were inverted onto slides and images taken immediately
at 40X magnification on anOlympus BX51 microscope
fitted with a U-LH100HE reflective fluorescence system
and equipped with a Diagnositic Instruments, Inc. SPOT
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camera and software. Chroma Technology Corp filter
sets were used for green (exciter: D480/30x, emitter:
535/40 m, beamsplitter: 505dclp), red (exciter: D540/
25x, emitter: 606/55 m, beamsplitter: 556dclp), and blue
(exciter: D360/40x, emitter: 460/50 m, beamsplitter:
400dclp). Scale bar equals 20 μm.
Dye retention analysis by flow cytometry
Cells were incubated with acridine orange (2 μg/mL) or
LysoTracker Green (25 nM) for 30 minutes at 37°C prior
to treatment with compounds for one hour. Cells were
washed and mean fluorescence quantified with a FACS-
Calibur flow cytometer (BD Biosciences, San Jose, CA).
Mean fluorescence was normalized to DMSO to deter-
mine the degree of lysosomal permeabilization. In
addition, cells were pretreated with concanamycin A
(10 μM) for one hour at 37°C prior to staining with ei-
ther SW120 or PB385 (100 nM) for 30 minutes at 37°C
and the difference in uptake represented by histogram.
Constructs
shRNAlentiviral constructs in pLKO.1 against human
LAMP1 was purchased from Sigma Aldrich, and follow-
ing verification of knockdown, clone ID NM_005561.2-
1183s1c1 used to compromise lysosomal integrity. Pack-
aging vectors were obtained through Addgene, Inc.
(Cambridge, MA). Lentivirus particles were prepared by
transfection of 293 T cells in T75 flasks with 3 μg con-
struct, 2.8 μgpRSV-Rev, 2.4 μgpMDLg/pRRE, and 0.6 μg
pMD2.G utilizing FuGENEW 6 Transfection Reagent
from F. Hoffmann-La Roche Ltd. (Basel, Switzerland).
Forty-eight and 72 hours following transfection, super-
natant was transferred to Bxpc3 cells in the presence of
polybrene (8 μg/mL). Transformed cells were selected
with puromycin (1 μg/mL) and assayed accordingly.
Antibody staining
Cells were washed once with PBS prior to fixation with
IC Fixation Buffer (eBiosciences) for 15 minutes at 37°C.
Fixed cells were washed with PBS, resuspended in
Permeabilization Buffer (eBiosciences), and incubated
for 30 minutes at room temperature. Intracellular anti-
gen staining was performed with FITC-antibody dilution
of 1:100 in Permeabilization Buffer for 60 minutes at
room temperature. Mean fluorescence in FL1 was quan-
tified with a FACSCalibur flow cytometer.
Cell viability
Cell lines maintained at optimal culture conditions were
seeded into 96-well white, clear-bottom plates and fol-
lowing treatment, viability determined with CellTiter-
Glo Luminescent Viability Assay from Promega (Madison,
WI). Luminescence was quantified with a SpectraMax
Gemini microplate spectrofluorometer from Molecular
Devices (Silicon Valley, CA). Viability relative to vehicle
was fit by non-linear regression and plotted against
concentration.
Cellular protease assay
Cells were treated in the presence of inhibitors and cyto-
solic extracts prepared using the digitonin extraction
method as previously described [43]. Washed cells were
resuspended at 1x106 cells/mL in extraction buffer con-
sisting of sucrose (250 mM), HEPES (20 mM), KCl
(10 mM), MgCl2 (1.5 mM), EDTA (1 mM), and digitonin
(30 μM). Cells were placed on ice on an orbital shaker
for 10 minutes prior to centrifugation for 1 min at
14,000 rpm at 4°C. Supernatants were collected and
20 μL used to detect cleavage of Z-RR-AMC in and
equal volume of reaction buffer consisting of sodium
acetate (100 mM), NaCl (200 mM), EDTA (4 mM), DTT
(10 mM), and Z-RR-AMC (10 μM). Plates were read fol-
lowing incubation at 37 ° for 60 minutes with Spectra-
Max Gemini microplate spectrofluorometer, Molecular
Devices (Silicon Valley, CA) (ex 355 nm, em 450 nm).
Detection of reactive oxygen species (ROS)
by flow cytometry
Cells were seeded into 12-well plates one day prior to
treatment, stained with 25 μM 5-(and-6)-carboxy-2’,7’-
dichlorodihydro-fluorescein diacetate (carboxy-
H2DCFDA) (Image-iT Live Green Reactive Oxygen Spe-
cies Detection Kit, Molecular Probes, Eugene, OR) for
30 minutes at 37°C and treated overnight. Fluorescence
intensity (max 529 nM) was quantified in the FL1 chan-
nel with a FACSCalibur flow cytometer.
Caspase-3 activity
Cells were maintained at optimal conditions and seeded
in 96-well black-bottom plates in a volume of 100 μL.
Following treatment, 5X assay buffer containing EDTA
(10 mM), CHAPS (5 %), HEPES (100 mM), DTT
(25 mM), and Ac-DEVD-AMC (250 μM) was added dir-
ectly to the cell media and incubated for two hours at
37°C on a microplate shaker, and liberated AMC quanti-
fied with a SpectraMax Gemini microplate spectrofluo-
rometer, Molecular Devices (ex 355 nm, em 450 nm).
Caspase-3 activity is normalized to the absence of
inhibitor.
Statistical analysis
Statistical analysis and data plotting was conducted
using GraphPad Prism (GraphPad Software, San Diego,
CA). Data represents the mean± SEM. Viability IC50
values at 18 hours were calculated by line fitting normal-
ized viability versus concentration with non-linear re-
gression and statistical significance determined using
one-way ANOVA. Differences in viability, caspase-3
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activity, apoptosis, and oxidation status were analyzed
using two-way ANOVA to identify differences and con-
firmed with paired two-tailed t-tests. Blood cytology and
biochemistry results were analyzed using one-way
ANOVA with Tukey’s multiple comparison test. Statis-
tical analysis for the difference in tumor volume between
treatments groups was determined with the repeated
measures ANOVA. Kaplan-Meier survival curves were
plotted and differences compared with a log-rank test. A
p-value of less than 0.05 was considered significant for
all tests.
Additional files
Additional file 1: Figure S1. In vivo efficacy of sigma-2 receptor
ligands. Female C57BL/6 mice inoculated subcutaneously with 1x106
Panco2 cells were treated daily with sigma-2 receptor ligands when
tumors reached an average of 5 mm in diameter. Data represents mean
± SEM, n = 7–10 per group. Mice received daily treatment through the
duration presented.
Additional file 2: Figure S2. Colocalization of SW120 and PB385 in
Bxpc3 and Aspc1 pancreatic cancer cell lines by fluorescence microscopy.
Live cells were imaged following incubated with LysoTracker Red (50
nM), red, and fluorescent sigma-2 receptor ligand (500 μM), green, for 30
minutes at 37°C prior to nucleic acid counterstaining with Hoechst, blue,
scale bar = 20 μm.
Additional file 3: Figure S3. Lysosomal membrane permeabilization
comparison between Bxpc3 and Aspc1 pancreatic cancer cell lines. (A)
Acridine orange (2 μg/mL) staining for lysosomal integrity by
fluorescence microscopy in Bxpc3 cells, top row, and Aspc1, bottom row,
treated with vehicle, PB282 (30 μM), SW43 (30 μM), or CMA (10 nM) for
one hour, scale bar = 20 μm. Flow cytometric analysis of acridine orange
stained cells following treatment with sigma-2 receptor ligands, CMA, or
HCQ as positive control. FL3 = orange, FL1 = green. (B) Confirmation of
lysosomal membrane permeabilization with LysoTracker Green following
same treatments as above in Bxpc3 and Aspc1 cells. (C) Overall caspase-3
activity compared between Bxpc3 and Aspc1 cell lines following
treatment with SW43 (30 μM), PB282 (90 μM), or HCQ (90 μM). (D)
Viability of Aspc1 cells following 24 hour treatment with SW43, PB282, or
HCQ. Data represents percent viability compared to DMSO treated cells,
n = 3, * p < 0.05.
Abbreviations
(LMP): Lysosomal membrane permeabilization; (NAC): N-acetylcysteine; (α-
toco): α-tocopherol; (AO): acridine orange; (CMA): concanamycin A;
(HCQ): hydroxychloroquine; (DMSO): dimethyl sulfoxide; (ROS): reactive
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2-oxa-1,3-diazol-4-yl)hexanamine; (SW120): N-9-(10-(7-nitrobenzo-2-oxa-1,3-
diazol-4-ylamino)decyl)-9-azabicyclo[3.3.1]nonan-3a-yl-N-(2-methoxy-5-
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